Top Page
Alnylam Pharma
(NASDAQ:ALNY)
Alnylam Pharma (ALNY) vs. SPDR S&P 500 ETF (SPY)
Alnylam Pharma Business Overview & Revenue Model
Alnylam Pharma Key Performance Indicators (KPIs)
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.
Main Street DataAlnylam Pharma Earnings Call Summary
Alnylam Pharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.46B | 2.25B | 1.83B | 1.04B | 844.29M | 492.85M |
| Gross Profit | 2.06B | 1.92B | 1.52B | 868.60M | 704.14M | 414.80M |
| EBITDA | -170.93M | -178.85M | -258.24M | -926.56M | -661.56M | -736.33M |
| Net Income | -319.09M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M |
Balance Sheet | ||||||
| Total Assets | 4.57B | 4.24B | 3.83B | 3.55B | 3.64B | 3.41B |
| Cash, Cash Equivalents and Short-Term Investments | 2.86B | 2.69B | 2.44B | 2.19B | 2.44B | 1.87B |
| Total Debt | 1.30B | 1.30B | 1.31B | 1.32B | 997.59M | 521.19M |
| Total Liabilities | 4.32B | 4.17B | 4.05B | 3.70B | 3.06B | 2.39B |
| Stockholders Equity | 250.59M | 67.09M | -220.64M | -158.22M | 588.20M | 1.02B |
Cash Flow | ||||||
| Free Cash Flow | -52.09M | -42.59M | 41.95M | -613.33M | -718.07M | -685.32M |
| Operating Cash Flow | -15.54M | -8.31M | 104.16M | -541.27M | -641.69M | -614.96M |
| Investing Cash Flow | -110.77M | -116.84M | -336.35M | 169.35M | -273.30M | -435.52M |
| Financing Cash Flow | 231.59M | 294.16M | 172.13M | 425.75M | 1.25B | 994.98M |
Alnylam Pharma Technical Analysis
Alnylam Pharma Risk Analysis
Alnylam Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $17.90B | 15.36 | 30.39% | ― | 18.09% | 3563.21% | |
| ― | $51.08B | 39.29 | 24.75% | ― | 89.58% | ― | |
| ― | $108.04B | 30.03 | 22.77% | ― | 10.38% | ― | |
| ― | $17.93B | 14.43 | 26.08% | ― | 23.25% | 64.46% | |
| ― | $62.38B | ― | -257.82% | ― | 5.01% | -330.09% | |
| ― | $25.25B | ― | -1.81% | ― | 7.51% | 30.53% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Alnylam Pharma Corporate Events
Study Overview: Alnylam Pharmaceuticals, in collaboration with Regeneron Pharmaceuticals, is conducting a Phase 1 study titled A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer’s Disease. The study aims to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of ALN-5288 in patients with Alzheimer’s Disease, marking a significant step in addressing this challenging condition.
On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of America and other lenders, securing a $500 million revolving line of credit. This agreement, which includes a $150 million letter of credit sublimit, allows Alnylam to use the funds for working capital and general corporate purposes. The credit facility is subject to various financial covenants, including maintaining specific leverage and interest coverage ratios, and is secured by the company’s assets. The maturity date for the credit facility is September 30, 2030, with provisions for early maturity under certain conditions.
The most recent analyst rating on (ALNY) stock is a Buy with a $471.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
Alnylam Pharmaceuticals recently completed a Phase 1 clinical study titled A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers. The study aimed to assess the safety, tolerability, and pharmacokinetics of ALN-AGT01 RVR, a new drug candidate, in healthy adults. This research is significant as it lays the groundwork for future clinical trials and potential therapeutic applications.
Alnylam Pharma has engaged in financial maneuvers involving convertible senior notes. The company offered and sold notes to initial purchasers under exemptions from registration, with potential issuance of up to 1,381,483 shares of common stock upon conversion. Concurrently, Alnylam executed note repurchase transactions, buying back approximately $637.8 million of its 1.00% convertible senior notes due 2027 for around $1,105.8 million, influenced by market conditions.
The most recent analyst rating on (ALNY) stock is a Buy with a $515.05 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
On September 8, 2025, Alnylam Pharmaceuticals announced a proposed private offering of $500 million in convertible senior notes due 2028, targeting qualified institutional buyers. The offering aims to support capped call transactions and repurchase existing notes, potentially impacting Alnylam’s stock market activity and conversion price. The company plans to use the proceeds for these financial strategies and general corporate purposes, with implications for its market positioning and stakeholder interests.
The most recent analyst rating on (ALNY) stock is a Buy with a $470.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
Alnylam Pharmaceuticals is conducting a Phase 3 study titled ‘TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.’ The study aims to assess the effectiveness of nucresiran in reducing mortality and cardiovascular events in patients suffering from this condition, while also evaluating its impact on patients’ health status and quality of life.
Study Overview: Alnylam Pharmaceuticals is conducting an open-label extension study titled An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. The study aims to gather data on the safety, efficacy, and pharmacodynamics of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, either continuing or switching from patisiran. This research is significant as it addresses a critical need for effective treatments for this rare condition.
Study Overview: Alnylam Pharmaceuticals is conducting a Phase 2 trial titled ‘A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA).’ The study aims to assess the impact of ALN-APP on CAA disease progression and evaluate its safety and tolerability in patients with sporadic and Dutch-type CAA.
Study Overview: Alnylam Pharmaceuticals is conducting a study titled ‘ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP).’ The study aims to understand the natural history and real-world management of AHP, as well as evaluate the safety and effectiveness of givosiran and other approved therapies. This research is significant as it seeks to enhance the understanding of AHP and improve treatment strategies.
Alnylam Pharmaceuticals is conducting a clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer’s Disease (EOAD)’. The study aims to assess the safety and tolerability of ALN-APP, a drug administered via intrathecal injection, in patients with EOAD. This research is significant as it explores potential treatments for a challenging condition.
Study Overview: Alnylam Pharmaceuticals is conducting an observational study titled NeuroFeeL Study to evaluate Neurofilament Light Chain (NfL) levels as a biomarker in asymptomatic carriers of Transthyretin (TTR) gene variants and patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. The study aims to assess NfL’s potential for diagnosing, detecting disease onset, monitoring progression, and evaluating treatment response, which could significantly enhance patient management and outcomes.
Alnylam Pharmaceuticals is conducting a global observational study titled ‘ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)’. The study aims to describe the epidemiological and clinical characteristics, natural history, and real-world management of ATTR amyloidosis patients. It also seeks to assess the safety and effectiveness of patisiran and vutrisiran in routine clinical practice, and to observe disease progression in pre-symptomatic carriers of a TTR variant.
Study Overview: Alnylam Pharmaceuticals is conducting a study titled A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington’s Disease. The study aims to assess the safety and effectiveness of ALN-HTT02, a potential treatment for Huntington’s Disease, a progressive brain disorder.
Alnylam Pharmaceuticals is conducting a study titled ‘Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program’ to assess pregnancy outcomes in women exposed to patisiran-LNP. This study aims to gather data on pregnancy complications and fetal/neonatal outcomes, providing crucial insights into the safety of this treatment during pregnancy.
Study Overview: Alnylam Pharmaceuticals is conducting a Phase 1 study titled A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma. The study aims to assess the safety, tolerability, and antitumor activity of ALN-BCAT, both alone and with pembrolizumab, in patients with advanced stages of liver cancer. This research is significant as it explores new treatment avenues for a challenging condition.
Alnylam Pharmaceuticals is conducting a study titled ‘An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.’ The study aims to gather data on the safety, efficacy, and pharmacodynamics of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, focusing on those continuing or switching from patisiran.
Study Overview: Alnylam Pharmaceuticals is conducting an open-label extension study titled An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. The study aims to gather safety, efficacy, and pharmacodynamic data on vutrisiran for patients with transthyretin amyloidosis with cardiomyopathy, either continuing from previous use or switching from patisiran. This research is significant as it seeks to provide insights into long-term treatment options for this condition.
Alnylam Pharmaceuticals’ recent earnings call for Q2 2025 was marked by a positive sentiment, driven by strong revenue growth and successful product launches. Despite some challenges, such as decreased collaboration revenue and increased operating expenses, the company’s significant achievements and robust financial performance set an optimistic tone for the future.
Alnylam Pharmaceuticals, Inc., a leader in RNA interference (RNAi) therapeutics, focuses on developing innovative medicines for rare and prevalent diseases, leveraging Nobel Prize-winning science to transform patient care.
Study Overview: Alnylam Pharmaceuticals is conducting a study titled ‘A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer’s Disease (EOAD)’. The primary goal is to assess the safety and tolerability of ALN-APP in patients with EOAD, which could provide significant insights into treatment options for this challenging condition.
Alnylam Pharmaceuticals is conducting a Phase 1 clinical study titled A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneously Administered ALN-TTRSC04 in Healthy Subjects. The study aims to assess the safety and tolerability of ALN-TTRSC04, a drug administered via subcutaneous injection, in healthy individuals. This research is significant as it explores the pharmacokinetics and pharmacodynamics of the drug, potentially paving the way for new treatments.